What top creators are saying about Eli Lilly and Company(LLY)— Page 4

Extremely optimistic view based on its pipeline drug retatrutide, described as a potential 'miracle drug' and 'blockbuster' that could be superior to current GLP-1s.

AI is expected to create massive opportunities in healthcare for companies like Eli Lilly, particularly for services like 'Lilly Direct'. However, significant regulatory hurdles in Western countries are a key risk that could slow down monetization.

Significant advertising spend on the new drug EpGliss suggests high expectations as a future revenue driver. The launch and market reception are critical indicators of the company's growth pipeline and future earnings potential.

The speaker's bearish view on GLP-1 drugs, due to their perceived negative impact on human drive, poses a long-term, non-financial risk to the company as part of the broader sector.

HIMS made a very smart strategic decision to never offer compounded versions of Lilly's drug, which is seen as a key advantage and de-risking factor, as it avoids conflict with the 'jewel of healthcare in America'.

At the forefront of the lucrative weight-loss drug market. Its drug, retatrutide, was singled out as a potential trillion-dollar drug. Potential new regulations restricting competition would be a massive bullish event.

The discussion of GLP-1 drugs' measurable public health impact signals a large and growing market, which could be a long-term tailwind for the pharmaceutical companies that dominate this space, such as Eli Lilly.

The speaker is very bullish, predicting the weight loss market will 'likely belong to Lilly towards year-end 2026' due to its superior product pipeline, particularly its upcoming drug Ritatrudide.

Mentioned as a 'Big Pharma' company defending its drug patents against compounding pharmacies like Hims. Its drug pipeline, including future drug retatrutide, could make current legal battles obsolete.

The speaker is extremely bullish, predicting LLY will 'own the entire market' for weight-loss drugs by late 2026 with its next-generation drug, retatrutide, making it a better long-term investment than NVO.

Considered to be 'winning the weight loss drug wars' after reporting earnings and revenue that crushed expectations and guiding for 25% revenue growth.

The company can 'tweak these medicines' (GLP-1s) to create new versions targeting specific conditions beyond weight loss, such as cardiovascular health, massively expanding the potential market. It is a key player to watch in a 'game-changing' technology sector.

The company is described as 'growing very meaningfully' and gaining strength, with its stock up 10% after earnings. It is seen as having a competitive advantage over its main rival.

Bullish outlook, positioned as a strong, long-term leader and innovator in the weight-loss drug market. Its future pipeline, including the drug Retatrutide, is seen as a significant catalyst.

Viewed as the clear winner in the GLP-1 market, with revenue up 43%, a raised 2026 revenue guidance to $80 billion, and confidence it will dominate the market.

Highlighted for its strong earnings and an 8% gain on a red market day. Part of a resilient sector using AI to bring drugs to market 'much more rapidly and much more cheaply,' which should help it 'outperform'.

The stock was up 7-8% after 'crushing' earnings, with revenue up 43% year-over-year, demonstrating exceptional strength and positioning it as a potential safe haven.

The massive growth runway for GLP-1 drugs is considered a major tailwind for leading pharmaceutical companies in the space, including Eli Lilly.

The dramatic price reduction and inclusion of its GLP-1 drugs in Medicare/Medicaid plans could massively expand the addressable market, and its innovation pipeline with drugs like Retatrutide indicates a potential for maintaining a competitive advantage.

Has significant exposure to the psychiatric drug market through Prozac and Zyprexa, but faces potential reputational and legal risks due to detailed negative patient experiences with these specific drugs, particularly Zyprexa.

Its partnership with NVIDIA is cited as an example of a positive trend: applying AI to optimize clinical trials and make the drug development process more efficient.

The GLP-1 drug theme represents a major growth driver for pharmaceutical companies in the space, including Eli Lilly (LLY), which makes similar drugs, reinforcing the idea that this is a long-term, transformative trend in healthcare.

Cited as a prime example of a potential acquisition target for Big Tech in a speculative, long-term M&A trend involving AI and pharma.

While the market for GLP-1 drugs is enormous, the potential for government-enforced price cuts in the US represents a significant risk to profitability.

Faces a significant risk from the anticipated market entry of over 10 cheaper, Chinese-made GLP-1 drugs, which will likely lead to a major price war and erode market share.

Partnering with NVIDIA to use cutting-edge AI for drug discovery, which could accelerate R&D and solidify its leadership position in the highly profitable pharma market.

Partnering with Nvidia in a $1 billion deal to create an AI drug discovery lab, which positions the company at the forefront of using advanced technology for pharmaceutical innovation.

Investing in an AI partnership with NVIDIA could dramatically shorten drug discovery timelines, reduce R&D costs, and increase the success rate of new medicines, giving the company a significant competitive advantage.

The company has significant leverage and pricing power due to its highly sought-after products (like Zetbound), allowing it to bypass the restrictive PBM system and control its distribution.

Partnering with NVIDIA to use AI to transform drug discovery, which is a significant positive development.

A small amount is held as a 'trade' rather than a long-term investment. Sentiment is neutral due to a lack of deep industry understanding and a noted risk of competition from 'gray market Chinese peptides'.

Experiencing significant revenue growth as a leader in the massive and rapidly expanding GLP-1 drug market, though investors should consider long-term risks like competition and side effects.

Mentioned as a potential acquirer in the pharma space, but the analysis prefers owning acquisition targets (biotech) rather than the large-cap acquirers.

Considered a market leader, but its high valuation reflects massive expectations for its GLP-1 pipeline. This creates a 'High Valuation Risk' of a significant price drop if it fails to meet lofty expectations or if competitors are more successful.

Highlighted as a stock showing strength and leadership within the healthcare sector, which is seen as a laggard where a 'turn is the real deal'.

The company 'looks fantastic' in the 'GLP wars' and has a major future catalyst in its oral pill Orpho. However, the speaker is cautious about significant upside from the current ~$1,000 price, citing valuation and patent cliff risks, though a model suggests a potential $1,100 valuation.

Very bullish, representing a theme where AI-driven drug discovery could lead to a re-rating of the entire pharma sector with higher valuation multiples, potentially replacing tech as a market leader.

Mentioned as a key competitor in the GLP-1 drug market that could be impacted by Novo Nordisk's upcoming oral pill.

A specific holding in the healthcare sector, which is viewed as a 'Growth at a Reasonable Price' (GARP) play with potential AI-driven upside.

Positioned as a key competitor to Novo Nordisk in the highly lucrative GLP-1 market. The mention of its drug, Monjaro, confirms the trend is a broader sector-wide boom, not a single-company phenomenon.

A strong performer, up 33%, as it 'seems to have won the obesity drug wars'.

Mentioned as a sector (healthcare) where money is rotating into from high-growth AI stocks.

The stock is mentioned as part of a sector rotation where capital is flowing from technology into healthcare, indicating a neutral market dynamic.

Up over 3%, cited as a primary beneficiary of a market rotation out of tech and into the healthcare sector.

Identified as a major pharmaceutical company at the forefront of GLP-1 development, which could be a massive new commercial opportunity for anti-aging treatments.

Could see its addressable market expand dramatically if anti-aging applications of its GLP-1 drugs are proven in humans.

While its legacy drug Prozac is now generic, the company is a major player in neuroscience, and an investment opportunity exists in its pipeline for developing safer, more effective mental health treatments.

The development of next-generation drugs that combine GLP-1s with myostatin inhibitors to prevent muscle loss could be a 'massive catalyst' for the company.

Mentioned as a 'prime example of a firm breaking out' in the AI drug discovery and longevity space, a sector described as having 'infinite' revenue potential.

Mentioned briefly as one of the speaker's 'good buys,' indicating a positive personal investment position.